Medicare Part D spending on GLP-1 diabetes drugs surges

Spending on GLP-1 diabetes drugs under Medicare Part D has surged in recent years, according to a KFF analysis, Fierce Healthcare reports. The study found that spending on Novo Nordisk's Ozempic rose from $56.8m in 2018 to $4.6bn in 2022. The report also noted increased spending on other GLP-1 drugs, with total spending on Ozempic, Novo's Rybelsus, and Eli Lilly's Mounjaro reaching $5.7bn in 2022.